S&CO Inc. lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.2% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 206,754 shares of the company’s stock after selling 396 shares during the period. Johnson & Johnson accounts for approximately 3.2% of S&CO Inc.’s portfolio, making the stock its 7th biggest position. S&CO Inc.’s holdings in Johnson & Johnson were worth $28,797,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Zions Bancorporation N.A. grew its position in Johnson & Johnson by 0.4% in the 2nd quarter. Zions Bancorporation N.A. now owns 20,173 shares of the company’s stock valued at $2,810,000 after acquiring an additional 73 shares in the last quarter. Cambridge Advisors Inc. grew its position in Johnson & Johnson by 0.3% in the 4th quarter. Cambridge Advisors Inc. now owns 22,436 shares of the company’s stock valued at $2,895,000 after acquiring an additional 78 shares in the last quarter. Vishria Bird Financial Group LLC grew its position in Johnson & Johnson by 3.0% in the 2nd quarter. Vishria Bird Financial Group LLC now owns 2,736 shares of the company’s stock valued at $381,000 after acquiring an additional 80 shares in the last quarter. Burt Wealth Advisors grew its position in Johnson & Johnson by 0.6% in the 4th quarter. Burt Wealth Advisors now owns 12,898 shares of the company’s stock valued at $1,665,000 after acquiring an additional 82 shares in the last quarter. Finally, Timber Creek Capital Management LLC grew its position in Johnson & Johnson by 8.7% in the 4th quarter. Timber Creek Capital Management LLC now owns 1,035 shares of the company’s stock valued at $133,000 after acquiring an additional 83 shares in the last quarter. Institutional investors and hedge funds own 66.78% of the company’s stock.
Several equities analysts have weighed in on the company. Morgan Stanley lifted their target price on Johnson & Johnson from $134.00 to $145.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 17th. Goldman Sachs Group assumed coverage on Johnson & Johnson in a research report on Tuesday, May 28th. They issued a “buy” rating for the company. Barclays assumed coverage on Johnson & Johnson in a research report on Friday, June 21st. They issued a “hold” rating and a $140.00 target price for the company. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Finally, Credit Suisse Group set a $156.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research report on Thursday, July 18th. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $148.56.
In related news, Director Marillyn A. Hewson acquired 3,000 shares of the stock in a transaction dated Tuesday, June 11th. The stock was acquired at an average cost of $139.68 per share, with a total value of $419,040.00. Following the completion of the transaction, the director now owns 3,000 shares in the company, valued at approximately $419,040. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.23% of the company’s stock.
Shares of Johnson & Johnson stock traded up $0.78 on Friday, reaching $131.07. 6,573,218 shares of the company were exchanged, compared to its average volume of 7,695,500. Johnson & Johnson has a 1-year low of $121.00 and a 1-year high of $148.99. The company has a market capitalization of $343.86 billion, a P/E ratio of 16.02, a P/E/G ratio of 2.20 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.13 and a current ratio of 1.33. The stock’s 50 day moving average is $136.70.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The business had revenue of $20.56 billion during the quarter, compared to the consensus estimate of $20.39 billion. During the same period in the previous year, the company posted $2.10 earnings per share. The business’s revenue for the quarter was down 1.3% on a year-over-year basis. On average, equities research analysts expect that Johnson & Johnson will post 8.6 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be given a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.90%. The ex-dividend date of this dividend is Monday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 46.45%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: Why investors pay attention to retained earnings
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.